Abstract:
Octahydro-pyrrolo[3,4-b]pyrrole derivatives are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Octahydro-pyrrolo[3,4-b]pyrrole compounds, methods for using such compounds, compositions for making them, and processes for preparing such compounds are disclosed herein.
Abstract:
formas cristalinas de inibidores de quinase. a presente invenção se refere a uma base livre de n-(4-{4-amino-7-[1-(2-hidroxietil)-1h-pirazol-4-il]tieno[3,2-c]piridin-3-il}fenil)-n -(3-fluorofenil) ureia e as formas cristalinas da mesma que são ingredientes farmacêuticos adequados para composições farmacêuticas uteis úteis no tratamento de doença, por exemplo, cãncer.
Abstract:
OCTAHYDRO-PYRROLO[3,4-B]PYRROLE DERIVATIVES ARE USEFUL IN TREATING CONDITIONS OR DISORDERS PREVENTED BY OR AMELIORATED BY HISTAMINE-3 RECEPTOR LIGANDS. OCTAHYDRO PYRROLO[3,4-B]PYRROLE COMPOUNDS, METHODS FOR USING SUCH COMPOUNDS, COMPOSITIONS FOR MAKING THEM, AND PROCESSES FOR PREPARING SUCH COMPOUNDS ARE DISCLOSED HEREIN.
Abstract:
N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N'-(3-fluorophenyl)urea free base and crystallines form thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.
Abstract:
Раскрытыоктагидропирроло[3,4-b]пиррольныепроизводныеформулы I и II, пригодныедлялечениясостоянийилирасстройств, которыепредотвращаютсяилиоблегчаютсяс помощьюлигандоврецепторагистамина-3.Раскрытыоктагидропирроло[3,4-b]пиррольныесоединения, применениетакихсоединений, композиции, содержащиеэтисоединения, испособыполучениятакихсоединений.
Abstract:
Octahydro-pyrrolo[3,4-b]pyrrole derivatives are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Octahydro-pyrrolo[3,4-b]pyrrole compounds, methods for using such compounds, compositions for making them, and processes for preparing such compounds are disclosed herein.
Abstract:
Octahydro-pyrrolo[3,4-b]pyrrole derivatives are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Octahydro-pyrrolo[3,4-b]pyrrole compounds, methods for using such compounds, compositions for making them, and processes for preparing such compounds are disclosed herein.Figure 1
Abstract:
Salts of N-(4- {4-amino-7-[ 1 -(2-hydroxyethyl)- 1 H-pyrazol-4-yl]thieno[3,2-c]pyridin- 3-yl}phenyl)-N'-(3-fluorophenyl)urea and crystalline forms thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.
Abstract:
OCTAHYDRO-PYRROLO[3,4-B] PYRROLE DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTOR LIGANDS Octahydro-pyrrolo[3,4-b]pyrrole derivatives are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Octahydro-pyrrolo[3,4-b]pyrrole compounds, methods for using such compounds, compositions for making them, and processes for preparing such compounds are disclosed herein.
Abstract:
N-(4-{4-amino-7-[1-(2-hidroxietil)-1H-pirazol-4-il]tieno[3,2-c]piridin-3-il}fenil)-N’-(3-fluorofenil)urea como base libre y formas cristalinas de la misma que son ingredientes farmacéuticos apropiados para hacer composiciones farmacéuticas útiles para el tratamiento de enfermedades, por ejemplo, cáncer. Proceso de obtención, composiciones farmacéuticas.Reivindicación 1: El compuesto N-(4-{4-amino-7-[1-(2-hidroxietil)-1H-pirazol-4-il]tieno[3,2-c]piridin-3-il}fenil)-N’-(3-fluorofenil)urea en una forma cristalina sólida, caracterizado porque la forma cristalina es la Forma I de la base libre, caracterizada por lo menos por un pico de difracción de rayos X en polvo en una o más cualesquiera de las siguientes posiciones: 7,20, 8,37, 11,38, 16,75, 16,95, 19,60, 22,04, y 22,86º 2q, ± 0,2º 2q. Reivindicación 13: El compuesto N-(4-{4-amino-7-[1-(2-hidroxietil)-1H-pirazol-4-il]tieno[3,2-c]piridin-3-il}fenil)-N’-(3-fluorofenil)urea en una forma cristalina sólida, caracterizado porque la forma cristalina es la base libre en la Forma II, caracterizada por lo menos por un pico de difracción de rayos X en polvo en una o más cualesquiera de las siguientes posiciones: 7,30, 8,81, 11,32, 15,08, 16,79, 19,46, 22,22, 22,70, 23,37, 24,29, 24,61, 25,07º 2q, ±@@@0,2º 2q.